|
General Account - Intramural Support
|
GenAcctIntSupp15
|
$2,763,728
|
$2,763,728
|
Unknown, Unknown
|
N/A
|
|
"""01-ENTERPRISE OPERATIONS MANAGER (PERPETUAL); VMTURBO, INC -- CATALOG : EOM-PE
|
316201500050W*2
|
$181,822
|
$181,822
|
N/A
|
"AFFIGENT, LLC"
|
|
"""BROAD INSTITUTE, INC.; HHSN261201400006C; CANCER GENOMICS CLOUD PILOTS; FY 15
|
261201400006C*2
|
$2,526,537
|
$2,526,537
|
N/A
|
"BROAD INSTITUTE, INC., THE"
|
|
"""02-HP DESIGNJET T920 POSTSCRIPT EPRINTER - 36 LARGE-FORMAT PRINTER - COLOR - I
|
316201500039W*2
|
$19,817
|
$19,817
|
N/A
|
"KOI COMPUTERS, INC."
|
|
SMART FUSION: HIGH AFFINITY PEPTIDE CAPTURE REAGENTS
|
261201500030C
|
$1,000,000
|
$1,000,000
|
HAYASHI, JUN
|
A&G PHARMACEUTICAL, INC
|
|
KS-Detect: A solar-powered and smartphone integrated instrument for point-of-care
|
1R43CA193096-01
|
$224,835
|
$224,835
|
JIANG, LI
|
A'AS, INC.
|
|
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for
|
4R42CA171552-02
|
$924,745
|
$924,745
|
DESAI, NEIL
|
AADI, LLC
|
|
Multiplexed DeNAno Protein Assay and Quantitation: Sequencing Based Proteomics
|
1R43CA193128-01
|
$225,000
|
$225,000
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Activin A antagonist for treatment of cancer-associated cachexia
|
1R43CA203180-01
|
$225,000
|
$225,000
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Development of Tumor Proliferation PET Tracer FLT using a Low Cost Single Dose Au
|
1R44CA195831-01
|
$222,828
|
$222,828
|
KHACHATURIAN, MARK
|
ABT MOLECULAR IMAGING, INC.
|
|
Hybridoma free multiplex approach for accelerating mouse monoclonal antibody gene
|
1R43CA193101-01
|
$224,781
|
$224,781
|
TRAN, HIEP
|
ABZYME THERAPEUTICS, LLC
|
|
A Rewards Program Contributing to Healthier Eating in Restaurants & Schools
|
5R44CA192374-03
|
$904,729
|
$904,729
|
LOPEZ, NANETTE
|
ACCENTS ON HEALTH, INC.
|
|
Minimally Invasive High Intensity Ultrasound Treatment of Uterine Fibroids
|
5R44CA121740-03
|
$640,042
|
$640,042
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Targeting B-cell lymphoma with Leukothera-phase II
|
5R42CA173900-03
|
$894,222
|
$894,222
|
BELINKA, BENJAMIN
|
ACTINOBAC BIOMED, INC.
|
|
1 GRAM OF MI-503
|
261201500212P
|
$6,200
|
$6,200
|
UNKNOWN, UNKNOWN
|
ACTIVE BIOCHEMICALS CO. LIMITED
|
|
3 GRAMS OF THE OICR-9429 COMPOUND; MUST HAVE DATA TO SUPPORT THE HIGH PURITY/QUA
|
261201500336P
|
$6,400
|
$6,400
|
UNKNOWN, UNKNOWN
|
ACTIVE BIOCHEMICALS CO. LIMITED
|
|
IeDEA West -Africa collaboration
|
5U01AI069919-10
|
$225,000
|
$225,000
|
Dabis, Francois
|
ADERA
|
|
A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer
|
1R43CA189613-01A1
|
$224,879
|
$224,879
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, INC.
|
|
"""BASE YEAR FOR ADMIN 3 SUPPORT FOR CBIIT - 1920 HOURS AT $39.91 PER HR. POP: AP
|
263201000015I*1
|
$76,627
|
$76,627
|
N/A
|
ADVANCED AUTOMATION TECHNOLOGI
|
|
Detection of Rare Oncogenic Gene Fusions in Non-small Cell Lung Cancer Using Cyto
|
1R43CA192728-01
|
$269,741
|
$269,741
|
MA, XIAO-JUN
|
ADVANCED CELL DIAGNOSTICS, INC.
|
|
Automated Ultrasensitive Detection of Light Chain Restriction in Lymphoproliferat
|
5R44CA168019-03
|
$529,530
|
$529,530
|
MA, XIAO-JUN
|
ADVANCED CELL DIAGNOSTICS, INC.
|
|
IAA BETWEEN NCI/DCCPS AND AGENCY FOR HEALTHCARE RESEARCH QUALITY (AHRQ), MEPS PR
|
APC15003001
|
$265,002
|
$265,002
|
UNKNOWN, UNKNOWN
|
AHRQ - AGENCY FOR HEALTHCARE RESEARCH &
|
|
TOPIC 339 - PHASE I CONTRACT - AKRIVIS TECHNOLOGY - PO: DEEPA NARAYANAN - CO: AND
|
261201500054C
|
$299,920
|
$299,920
|
UNKNOWN, UNKNOWN
|
AKRIVIS TECHNOLOGIES, LLC
|
|
Intraoperative assessment of non-melanoma skin cancer margins using NIRF probes.
|
2R44CA180296-02
|
$792,080
|
$792,080
|
STRAIGHT, BRIAN
|
AKROTOME IMAGING, INC.
|
|
Diffusion Weighted Breast MR Imaging for Screening Women with Dense Breasts
|
5R44CA186313-03
|
$676,958
|
$676,958
|
PENN, ALAN
|
ALAN PENN AND ASSOCIATES, INC.
|
|
Paracrine regulation of angiogenesis through integrin crosstalk
|
5F31CA174198-03
|
$27,120
|
$27,120
|
LONGMATE, WHITNEY
|
ALBANY MEDICAL COLLEGE
|
|
ENHANCING ONCOLYTIC VIROTHERAPY WITH TYPE III INTERFERON
|
7R21CA175802-03
|
$171,825
|
$171,825
|
ROBEK, MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
Women's Interagency HIV Study (WIHS-V)
|
5U01AI035004-22
|
$96,247
|
$96,247
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Central Africa IeDEA
|
5U01AI096299-05
|
$49,132
|
$49,132
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
6U54CA190163-02
|
$701,198
|
$701,198
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-02
|
|
$0
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
5U01CA078527-17
|
|
$0
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
6U01CA078527-18
|
$581,591
|
$581,591
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Tumor microenvironments determing migration, dissemination and dormancy
|
3U54CA163131-04S1
|
$20,366
|
$20,366
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Tumor microenvironments determing migration, dissemination and dormancy
|
3U54CA163131-05S1
|
$54,254
|
$54,254
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
MOTILITY AND INVASION
|
5P01CA100324-12
|
|
$0
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Tumor microenvironments determing migration, dissemination and dormancy
|
6U54CA163131-05
|
$426,161
|
$426,161
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer
|
2R01CA128943-06A1
|
$175,062
|
$175,062
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid
|
5R01CA167839-03
|
$172,015
|
$172,015
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer
|
6R01CA128943-07
|
$221,563
|
$221,563
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid
|
6R01CA167839-04
|
$174,510
|
$174,510
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-18
|
$294,353
|
$294,353
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Expanded Phase II Trial of Carraguard for Prevention of HPV Infection
|
6R01CA148966-06
|
$1
|
$1
|
EINSTEIN, MARK
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The role of macroH2A variants in cancer and senescence
|
5R01CA155232-04
|
$64,359
|
$64,359
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The role of macroH2A variants in cancer and senescence
|
6R01CA155232-05
|
$282,166
|
$282,166
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
6R01CA178394-02
|
$346,525
|
$346,525
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-17
|
|
$0
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Proton-coupled folate/antifolate transport
|
6R01CA082621-18
|
$486,473
|
$486,473
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Rac1 regulates protrusion and invasion of breast cancers in 3D
|
5R21CA181838-02
|
|
$0
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Rac1 regulates protrusion and invasion of breast cancers in 3D
|
6R21CA181838-03
|
$217,935
|
$217,935
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
Total relevant funding to Cancer for this search: $3,491,053,858
|